← board
MXCT
distress 2/10 · well-funded / low risk$1.10-3%today-53% from 52w high
Revenue
pre-revenue
Liquidity
$148M
Runway
5.2 yrs
Shares 1y
+1%
Price & events
-11.6% over 6M
CatalystRating changeDilutionFinancingdashed = today
-3.1%
1D
-18.1%
1W
-6.0%
1M
+28.2%
3M
-4.7%
6M
-52.6%
1Y
-75.9%
2Y
—
5Y
-93.5%
All
Overview
- Market Cap
- $118.37M
- Volume
- 112.96K
- 52 Week Range
- $0.68 – $2.33
- Total Shares
- 107.12M
- Float Shares
- 97.63M
- Short %
- 1.43%
- % Held by Insiders
- 1.59%
- % Held by Institutions
- 68.16%
- RVOL
- 0.08x
- Beta
- 1.66
Pipeline · 0 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| No pipeline trials tracked. | |||||
Catalyst news & presentations · 5
- 2026-08-12Estimated 45%earningsEarningsEarnings releaseyahoo
- 2025-06-26withdrawalAIM delisting effectiveSEC 8-K
- 2025-01-30partnershipMaxCyte acquires SeQure Dx, a leader in on-target and off-target editing assessment, for $4.5M upfront plus up to $2.5M contingent consideration.SEC 8-K
- 2024-05-01partnershipMaxCyte Platform · Legend Biotech signed as SPL client in May 2024SEC 8-K
- 2024-03-01partnershipMaxCyte Platform · Be Biopharma signed as SPL client in March 2024SEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
strong buy · target $4 (+272% upside) · 4 analysts
- 2026-03-25Craig-HallumBuy
- 2025-08-11BTIGBuy → Neutral
- 2025-08-07William BlairOutperform → Market Perform
- 2025-03-12StifelBuy
Competitors
- none identified
Recent news
- 2026-07-21MaxCyte stock surges on Genentech technology license deal By Investing.com - Investing.com South Africa
- 2026-07-21MaxCyte stock surges on Genentech technology license deal - Investing.com
- 2026-07-21MaxCyte Enters Technology License Partnership With Genentech - marketscreener.com
- 2026-07-21Genentech licenses MaxCyte cell engineering technology By Investing.com - Investing.com Nigeria
- 2026-07-21Genentech licenses MaxCyte cell engineering technology By Investing.com - Investing.com South Africa
- 2026-07-21MaxCyte® Announces Multi-Platform Technology License Partnership with Genentech® to Advance Cell Therapy Development - The Manila Times
- 2026-07-21MaxCyte (MXCT) Proxy filing Summary - Quartr
- 2026-07-17MaxCyte (MXCT) The 44th Annual William Blair Growth Stock Conference Summary - Quartr
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.